Menopause Racial and Ethnic Disparities: What Every Woman Needs to Know

Why Race and Ethnicity Matter in Menopause Care

Your race and ethnicity are among the strongest predictors of what menopause will feel like for you, how long it will last, and whether you will get adequate treatment. This is not a minor statistical footnote. The Study of Women's Health Across the Nation (SWAN), which followed over 3,300 women across multiple racial and ethnic groups for more than two decades, showed that symptom type, frequency, duration, and treatment access all diverge significantly by race.

These differences arise from a mixture of biology, socioeconomic factors, chronic stress, structural racism in healthcare, cultural beliefs about menopause, and provider bias. Separating those threads is difficult, and the science is still catching up. What is clear is that a one-size-fits-all clinical approach fails a large portion of women.

Why SWAN Changed Everything

Launched in 1994 at seven U.S. Sites, SWAN enrolled white, Black, Hispanic, Chinese-American, and Japanese-American women aged 42 to 52 who had not yet reached menopause. It is the largest, longest-running multiethnic menopause cohort in the world. SWAN's baseline design was deliberately powered to detect racial and ethnic differences, which was unusual for its era.

Nearly every statistic cited in this article traces back to SWAN or its substudies. Significant gaps remain for American Indian/Alaska Native women, Pacific Islander women, and women of Middle Eastern or South Asian descent, because they were not enrolled in SWAN at representative numbers. That absence is itself a health equity problem.

Structural Racism as a Biological Force

Chronic stress from discrimination alters hypothalamic-pituitary-adrenal axis function, raises cortisol, and may worsen vasomotor symptoms. The Weathering Hypothesis, proposed by epidemiologist Arline Geronimus, describes accelerated biological aging in Black women from cumulative exposure to socioeconomic adversity and racism. This framework helps explain why Black women enter a higher-symptom menopause trajectory even after adjusting for income and education.

Hot Flashes and Night Sweats: The Racial Gap Is Wide

Vasomotor symptoms (VMS), meaning hot flashes and night sweats, are the most studied menopause symptom across racial groups, and the differences are striking.

SWAN data show the following frequency of "bothersome" hot flashes in the menopausal transition:

| Racial/Ethnic Group | Prevalence of Bothersome VMS | |---|---| | Black women | ~45.6% | | Hispanic women | ~35.4% | | White women | ~31.2% | | Chinese-American women | ~20.5% | | Japanese-American women | ~17.6% |

Duration Matters as Much as Frequency

It is not just how often hot flashes occur. How long they persist differs sharply by race. A 2015 SWAN analysis published in JAMA Internal Medicine found that the median total VMS duration was:

• Black women: 10.1 years
• Hispanic women: 8.9 years
• White women: 6.5 years
• Chinese-American women: 5.4 years
• Japanese-American women: 4.8 years

Black women spent the most years in the VMS window, starting earlier in the menopausal transition and persisting longer after the final menstrual period. If you are a Black woman in your mid-40s noticing hot flashes, that experience may stretch well into your mid-50s without treatment.

What Drives the Black-White VMS Gap

Researchers have not isolated a single cause. Candidate factors include higher BMI on average (adipose tissue paradoxically increases VMS despite storing estrogen), lower physical activity levels linked to neighborhood safety and time poverty, higher rates of depression (which amplifies VMS perception), and hypothalamic sensitivity differences. One SWAN substudy found that psychosocial stress and financial strain independently predicted VMS severity after controlling for BMI and smoking.

Age at Menopause: Earlier Onset in Some Groups

Natural menopause in the U.S. Occurs on average at age 51 to 52 in white women. For other groups, the timing shifts.

SWAN data and supplementary analyses show:

• Hispanic women reach natural menopause approximately one year earlier, around age 50.
• Black women reach it around age 49.3 on average in some cohorts.
• Chinese-American and Japanese-American women tend to reach it slightly later, around 51 to 52.

The Indigenous Women Gap

American Indian and Alaska Native women are severely under-studied, but the Strong Heart Study found natural menopause occurring at a mean age of approximately 49 years in Indigenous women. Earlier menopause extends the post-menopause window, increasing cumulative years of estrogen deficiency and raising lifetime cardiovascular and osteoporosis risk.

Why Earlier Menopause Has Real Consequences

Each year of earlier menopause is associated with a measurable increase in cardiovascular disease risk. A 2019 meta-analysis in The Lancet Public Health found that women who reached natural menopause before age 50 had a 20% higher risk of coronary heart disease compared with those reaching menopause at 50 to 51. For Hispanic and Indigenous women who enter menopause earlier on average, this translates to a longer period of cardiovascular vulnerability without estrogen's protective effects.

Genitourinary and Sexual Symptoms: The Underreported Burden

Genitourinary syndrome of menopause (GSM), which includes vaginal dryness, painful sex, and urinary symptoms, is dramatically under-discussed across all racial groups, but the treatment gap is especially wide for women of color.

A 2019 analysis in Menopause found that Asian-American women reported fewer hot flashes but had comparable or higher rates of vaginal dryness and sexual discomfort compared to white women. Despite this, they were significantly less likely to have discussed GSM with a provider or received local estrogen therapy.

Cultural Shame and Provider Failure

In many East Asian, South Asian, and Latina cultural contexts, sexual symptoms are considered private or embarrassing to raise with a clinician. Providers who do not ask directly miss these symptoms entirely. If your provider has never asked you about painful sex or vaginal dryness, you can bring it up. Vaginal estrogen at very low doses is safe, effective, and does not carry the systemic risks associated with oral hormone therapy.

Black Women and GSM

Less SWAN data exist specifically on GSM in Black women, which is a gap the research community acknowledges. Black women are more likely to have untreated urinary incontinence, which shares some pathophysiology with GSM, and are less likely to have it addressed in primary care settings. The American Urogynecologic Society has documented racial disparities in pelvic floor disorder treatment access.

Bone Health Across Race: A Nuanced Picture

One of the most clinically consequential menopause-related racial differences involves bone. Black women have higher average bone mineral density (BMD) than white women across the life course, a biological difference well-documented in SWAN bone substudies. This led to a long-standing clinical assumption that Black women do not need osteoporosis screening.

That assumption is wrong, and it has cost lives.

The Screening and Fracture Paradox

Black women have lower rates of osteoporosis by DXA criteria, but when they do fracture, they have significantly higher post-fracture mortality than white women. They are also less likely to be offered DXA screening, less likely to be prescribed bisphosphonates after a fracture, and less likely to have calcium and vitamin D status assessed.

ACOG recommends DXA screening beginning at age 65 for all women, or earlier with risk factors. Race alone should not be used to delay screening conversations.

Hispanic Women and Bone Risk

Hispanic women have intermediate BMD between white and Black women, but higher rates of vitamin D deficiency, lower calcium intake on average, and higher rates of type 2 diabetes, all of which increase bone fragility. A 2020 study in the Journal of Bone and Mineral Research found that fracture risk in Hispanic postmenopausal women was underestimated by standard FRAX calculations that use race-adjusted inputs.

Hormone Therapy Access and Use: A Persistent Inequality

Hormone therapy (HT) is the most effective treatment for moderate-to-severe VMS, and The Menopause Society (NAMS) 2023 position statement confirms it is appropriate for healthy women under 60 or within 10 years of menopause onset. Yet who actually receives it is far from equal.

A 2021 analysis in Menopause found that Black women were approximately 40% less likely to use hormone therapy than white women, and Hispanic women were 30% less likely, even after adjusting for insurance status and education. The gap persisted across income levels.

Reasons Are Multiple and Interacting

Several forces converge to produce this gap:

• Provider bias. Clinicians are less likely to offer HT to Black and Hispanic women, sometimes citing cardiovascular risk without individualized assessment.
• Mistrust of the medical system. Rooted in documented historical abuses, including the Tuskegee study and forced sterilization programs targeting Black and Indigenous women, medical mistrust is rational, not irrational. Acknowledging this history matters.
• The Women's Health Initiative fallout. The 2002 WHI findings, which were later shown to apply primarily to older postmenopausal women not representative of typical HT candidates, caused a widespread drop in HT prescribing that hit Black and Hispanic women especially hard because they had less access to updated information and HT-knowledgeable providers.
• Lack of menopause-competent providers. A 2022 survey by The Menopause Society found that fewer than 10% of OB-GYNs and PCPs feel adequately trained to manage menopause. Women in underserved areas, who are disproportionately women of color, face the largest provider competency gaps.

What You Can Do

If you are being denied hormone therapy without a clear individualized reason, you can ask your provider to document why in your chart. You can also request a referral to a Menopause Society-certified menopause practitioner (NCMP), whose locator tool is at menopause.org.

Mental Health and Mood: Race-Specific Patterns

Depression risk rises during perimenopause across all groups, but the trajectory and context differ by race.

SWAN longitudinal data found that Black women had higher baseline depressive symptom scores at the start of the study, which some researchers attribute to cumulative socioeconomic stress rather than intrinsic biological difference. The rate of increase in depressive symptoms during the menopausal transition was similar across groups, suggesting the transition itself is a universal mood risk period regardless of race.

Hispanic women in SWAN showed a different pattern: higher rates of sleep disturbance, which is itself a driver of depression and cognitive symptoms during perimenopause. A SWAN sleep substudy found that Hispanic women were more likely to report difficulty sleeping and that poor sleep was a stronger predictor of depression in Hispanic than in white women.

The Invisible Burden of Racist Stress

A clinically useful framework for counseling women of color in perimenopause: distinguish between menopause-driven mood symptoms (which respond well to HT and/or SSRIs) and chronic allostatic load from racism-related stress (which requires different interventions, including trauma-informed care, community support, and systemic advocacy). Treating only the menopause component while ignoring the stress load produces partial and unsatisfying outcomes. Naming this distinction explicitly with patients is itself therapeutic. No clinical trial has formally tested this two-component counseling model in a randomized design, so this is a framework based on mechanistic evidence and clinical observation rather than RCT data.

Cardiovascular Risk After Menopause: The Racial Stakes Are Higher

Cardiovascular disease (CVD) is the leading cause of death in postmenopausal women of all races, but Black women carry a disproportionate burden. The American Heart Association's 2020 Go Red for Women report documented that Black women have the highest rates of hypertension of any U.S. Demographic group, with prevalence exceeding 55% by age 55.

Menopause accelerates CVD risk by eliminating estrogen's vasodilatory and lipid-modifying effects. For Black women who already enter menopause at higher cardiovascular risk and with higher hypertension prevalence, this acceleration happens on an already-compromised baseline.

Hispanic women have what epidemiologists call the "Hispanic paradox": despite lower average income and higher rates of diabetes and obesity, they have lower cardiovascular mortality than non-Hispanic white women. The mechanism is debated. It may involve nativity effects (immigrants tend to arrive healthier), dietary patterns, or social support networks. The paradox does not mean Hispanic women are low-risk; it means the risk profile is complex and should not be dismissed.

Lipids and Metabolic Shifts

SWAN's cardiovascular substudies documented that LDL cholesterol rises significantly in the two years surrounding the final menstrual period across all racial groups. Black women entered this transition with higher triglycerides and lower HDL on average. These lipid shifts, combined with earlier menopause onset and higher hypertension prevalence, make the case for earlier cardiovascular risk conversation in Black and Indigenous women at perimenopause.

The Evidence Gap: Who Is Missing From Menopause Research

You deserve to know where the evidence is thin for your group.

American Indian and Alaska Native women are the most under-represented group in menopause research. The Strong Heart Study provides some data on menopausal timing and cardiovascular outcomes, but VMS duration, GSM, bone outcomes, and HT use are poorly characterized in this population.

Pacific Islander women are nearly absent from U.S. Menopause cohorts. No SWAN-equivalent data exist.

South Asian women (Indian, Pakistani, Bangladeshi, Sri Lankan) are grouped into the broader "Asian" category in most studies, which obscures significant within-group variation. A 2021 analysis in Climacteric found that South Asian women reported higher rates of joint pain and sleep disturbance during perimenopause compared to East Asian women, differences that are lost in aggregate reporting.

Middle Eastern women are essentially absent from U.S. Menopause literature.

Women with intersecting marginalized identities (e.g., Black transgender women on hormone therapy, Indigenous women with disability) have essentially no dedicated menopause data.

When your provider cites "studies show" without specifying which population was studied, it is reasonable to ask, "Was this studied in women like me?"

Finding Care That Recognizes Your Full Picture

Getting good menopause care is harder than it should be, and harder still if you are a woman of color.

Practical steps:

1. Seek a Menopause Society-certified provider (NCMP). The NCMP credential requires specific menopause training. Find one at menopause.org.
2. Ask for a full cardiovascular risk assessment at perimenopause, not just at your annual physical. This means blood pressure, fasting lipids, fasting glucose, and a 10-year ASCVD risk calculation.
3. Request DXA screening if you have risk factors beyond age 65, including early menopause, low body weight, family history of hip fracture, long-term corticosteroid use, or tobacco use.
4. Bring your symptom log. Track hot flash frequency, sleep quality, mood, and sexual symptoms for two weeks before your appointment. The MenoPro app from The Menopause Society and the DESS (Daily Diary of Menopausal Symptoms) score are validated tools.
5. If your provider dismisses your symptoms, ask directly: "Based on my symptom severity and duration, am I a candidate for hormone therapy?" If the answer is no, ask for the specific contraindications in your case.

A Note on Perimenopause, Fertility, and Contraception

This article focuses on menopause transitions, not drug therapy, so a full pregnancy-and-lactation drug section does not apply here. However, two points are clinically necessary.

First, perimenopause is not infertility. Women can ovulate sporadically during perimenopause, and unintended pregnancy in this life stage is common. Black and Hispanic women have higher rates of unintended pregnancy in the late reproductive years. If you do not want to become pregnant, you need reliable contraception until you have been 12 consecutive months without a period (the standard WHO definition of menopause). ACOG Practice Bulletin 191 and ACOG's contraception guidance confirm that low-dose combined hormonal contraception can be used in perimenopausal women without smoking or cardiovascular risk factors and simultaneously manages VMS.

Second, menopause itself is a permanent, non-reversible state. It does not require contraception, but the perimenopausal transition preceding it absolutely does if pregnancy is not desired.